As this was a simulated use study, participants may not have experienced the same level of stress that they might experience during anaphylaxis.
Study was conducted by kaleo, Inc.
Learn more about the results of a retrospective claims analysis evaluating healthcare resource utilization and economic impact on patients prescribed AUVI-Q vs other epinephrine auto-injectors.
Present evidence on the healthcare-economic consequences of patients who experienced anaphylaxis5
Healthcare resource consumption was based on a 3-month episode of care following the index data of the anaphylaxis event.5
The objective of the study was to analyze healthcare resource use and costs of care in non-matched and matched patient populations who experienced anaphylaxis and were previously prescribed AUVI-Q vs other epinephrine auto-injectors (EAIs).5
This study was funded by Kaléo.
Download the study here.
Total costs of care during the 3 month post-index period excluding prescription costs were
$427 less
in the AUVI-Q cohort compared to the other EAI cohort.
Inpatient costs post index were
$162 less
for AUVI-Q patients, which is in line with the fewer hospitalizations observed among AUVI-Q patients.
VOICE INSTRUCTIONS
POCKET SIZED
AUTO-RETRACTABLE NEEDLE
AUVI-Q voice instructions remind patients to seek emergency medical care after use.
AUVI-q 0.1 mg was designed to mitigate the risk of needle injury when administering epinephrine to infants and toddlers 16.5 lbs-33 lbs.
To learn more about AUVI-q 0.1 mg designed for infants and toddlers click here.
Instruct caregivers to hold the leg of young children and infants firmly in place and limit movement prior to and during injection to minimize the risk of injection-related injury.1
Patients should seek emergency medical care immediately after use.
See the full details of these studies here.
In a randomized, cross-over usability study, untrained adults aged 18-65 years (N = 96) used 0.15 mg AUVI-Q and EpiPen Jr® trainers to simulate epinephrine administration to a child-sized manikin.
The untrained adults had no prior experience with epinephrine auto-injectors and were not provided with the devices prior to starting the simulation.
Key injection tasks were defined as the minimum tasks required for a patient to receive an epinephrine dose.
As this was a simulated use study, participants may not have experienced the same level of stress that they might experience during anaphylaxis.
Study was conducted by kaleo, Inc.
A study of 693 people aged 11 to 65 years was conducted to determine whether adults (N = 241), caregivers (N = 228), and children (N = 224) with and without EAI experience prefer using the AUVI-Q device compared to the EpiPen.
EpiPen® and EpiPen Jr® are registered trademarks of Mylan Inc.
We continue to closely engage with payers and insurance companies to expand formulary access for AUVI-Q. Effective August 2022, the list price for AUVI-Q is $598.00. Most patients do not pay list price. Out-of-pocket costs may vary based on insurance coverage. Kaléo remains committed to ensuring that eligible patients with commercial insurance, or those facing financial hardship, should be able to obtain AUVI-Q affordably through our access program. For additional questions or information, please contact our market access team at [email protected].
AUVI-Q® (epinephrine injection, USP) is a prescription medicine used to treat life-threatening allergic reactions, including anaphylaxis, in people who are at risk for or have a history of serious allergic reactions.
AUVI-Q is for immediate self (or caregiver) administration and does not take the place of emergency medical care. Seek immediate medical treatment after using AUVI-Q. Each AUVI-Q contains a single dose of epinephrine. AUVI-Q should only be injected into your outer thigh, through clothing if necessary. If you inject a young child or infant with AUVI-Q, hold their leg firmly in place before and during the injection to prevent injuries. Do not inject AUVI-Q into any other part of your body, such as into veins, buttocks, fingers, toes, hands, or feet. If this occurs, seek immediate medical treatment and make sure to inform the healthcare provider of the location of the accidental injection. Only a healthcare provider should give additional doses of epinephrine if more than two doses are necessary for a single allergic emergency.
Rarely, patients who use AUVI-Q may develop infections at the injection site within a few days of an injection. Some of these infections can be serious. Call your healthcare provider right away if you have any of the following symptoms at an injection site: redness that does not go away, swelling, tenderness, or the area feels warm to the touch.
If you have certain medical conditions, or take certain medicines, your condition may get worse or you may have more or longer lasting side effects when you use AUVI-Q. Be sure to tell your healthcare provider about all the medicines you take, especially medicines for asthma. Also tell your healthcare provider about all of your medical conditions, especially if you have asthma, a history of depression, thyroid problems, Parkinson’s disease, diabetes, heart problems or high blood pressure, have any other medical conditions, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. Epinephrine should be used with caution if you have heart disease or are taking certain medicines that can cause heart-related (cardiac) symptoms.
Common side effects include fast, irregular or ‘pounding’ heartbeat, sweating, shakiness, headache, paleness, feelings of over excitement, nervousness, or anxiety, weakness, dizziness, nausea and vomiting, or breathing problems. These side effects usually go away quickly, especially if you rest. Tell your healthcare provider if you have any side effect that bothers you or that does not go away.
Please see the full Prescribing Information and the Patient Information.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.